Is there such a thing as an over-the-counter GLP-1 supplement?

No. As of May 2026, every FDA-approved GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, orforglipron) is a prescription drug. No dietary supplement, over-the-counter pill, gummy, tea, drop, or powder contains a GLP-1 receptor agonist. Products marketed as 'GLP-1 supplements' or 'natural Ozempic' are typically berberine, capsaicin, fiber, chromium, apple cider vinegar, or proprietary herbal blends — none have GLP-1 receptor activity.

Does berberine work like Ozempic?

No. Berberine is a plant alkaloid that activates AMP-activated protein kinase (AMPK) and modestly lowers fasting glucose and HbA1c in type 2 diabetes (Yin et al., Metabolism 2008, PMID 18442638; Lan et al., J Ethnopharmacol 2015, PMID 25498346). The Amini 2020 meta-analysis of berberine on anthropometric measures (PMID 32147051) and the 2026 Elahi Vahed obesity meta-analysis (PMID 41310257) pool a small weight reduction of approximately 1-2 kg over 8-24 weeks. That mechanism is NOT GLP-1 receptor agonism. Semaglutide produces -14.9% body weight at 68 weeks (STEP 1, PMID 33567185); tirzepatide produces -20.9% at 72 weeks (SURMOUNT-1, PMID 35658024). The magnitude gap is roughly 10x.

Are FDA-approved GLP-1 medications regulated differently from supplements?

Yes — they are completely different regulatory categories. FDA-approved GLP-1 drugs (Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro, Victoza, Trulicity, Byetta, Bydureon, Rybelsus, Foundayo) went through New Drug Applications with Phase 1-3 clinical trials demonstrating safety and efficacy before FDA approval, and require a prescription from a licensed prescriber. Dietary supplements fall under the Dietary Supplement Health and Education Act of 1994 (DSHEA, 21 U.S.C. §§ 321(ff), 343(r), 343-2, 350b), which permits manufacturers to market a product as a supplement without FDA pre-approval. DSHEA prohibits supplements from making drug-disease claims, requires structure/function-claim disclaimers, and places the burden of safety substantiation on the manufacturer — not on FDA premarket review.

What about capsaicin, chromium, fiber, and apple cider vinegar?

Each has a small evidence base for modest effects on appetite, glycemia, or body weight — but none acts on the GLP-1 receptor. Capsaicin reduces ad-libitum energy intake by approximately 70-75 kcal/day in short-term trials (Whiting et al., Appetite 2014, PMID 24246368) via TRPV1-mediated brown adipose tissue thermogenesis (Yoneshiro and Saito, Curr Opin Clin Nutr Metab Care 2013, PMID 24100669). Soluble fiber improves satiety and modestly reduces body weight (Howarth et al., Nutr Rev 2001, PMID 11396693; Wanders et al., Obes Rev 2011, PMID 21676152). Chromium picolinate produced a small ~1.1 kg weight reduction of 'uncertain clinical relevance' in the Cochrane review (Tian et al., 2013, PMID 24293292). Apple cider vinegar systematic reviews (Launholt 2020 PMID 32170375; Castagna 2025 PMID 41010525) find limited evidence with high heterogeneity.

Are there FTC or FDA enforcement actions against 'natural Ozempic' supplements?

Yes. The FTC's case against Jason Cardiff and Redwood Scientific Technologies (172-3117-X190001, 2018; 2020 default judgment) is the most-cited federal precedent for false weight-loss claims on dietary patch and strip products and applies equally to 'natural Ozempic' supplement marketing. The FDA maintains a Tainted Weight Loss Products database identifying supplements found to contain undisclosed prescription drug ingredients (sibutramine, phenolphthalein, ephedra alkaloids). FDA Warning Letters routinely target supplement companies that make drug-disease claims about weight loss in marketing copy, which violates DSHEA's structure/function-claim limits.

Can a supplement help me lose weight even if it doesn't act on GLP-1?

Modestly, in some cases — but the mechanism is unrelated to GLP-1 and the magnitude is small. A few well-studied ingredients (soluble fiber, capsaicin, caffeine, green tea catechins) produce 1-3 lb of additional weight loss over 8-12 weeks in meta-analyses when added to a calorie-controlled diet. That is roughly 10x smaller than the effect of FDA-approved GLP-1 receptor agonists. If you choose to use a supplement, choose one with peer-reviewed RCT evidence, do not expect Ozempic-magnitude results, and understand the mechanism is appetite/thermogenesis/glycemia — not GLP-1 receptor activation.

Is There a GLP-1 Supplement? The Honest Evidence Review on 'Natural Ozempic' OTC Products

0OTC supplements with GLP-1 receptor activity

This evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Search Amazon, TikTok, or Instagram for “GLP-1 supplement,” “natural Ozempic,” or “GLP-1 support” and dozens of products promise the appetite-suppressant effects of Wegovy or Zepbound in a capsule, gummy, or drop — without a prescription. None of them contain a GLP-1 receptor agonist. The ingredients are typically berberine, capsaicin, soluble fiber, chromium picolinate, apple cider vinegar, or proprietary herbal blends. Each has its own evidence base — mostly modest effects on glycemia or appetite — but none acts on the GLP-1 receptor, and the effect sizes are roughly 10x smaller than the FDA-approved injectable and oral GLP-1 drugs.

The honest answer

No OTC supplement contains a GLP-1 receptor agonist. Products marketed as “GLP-1 supplements,” “natural Ozempic,” or “GLP-1 support” are typically berberine, capsaicin, fiber, chromium, apple cider vinegar, or proprietary herbal blends — none have GLP-1 receptor activity. At best they produce 1–2 lb of weight loss over 12 weeks via unrelated mechanisms (AMPK activation, TRPV1 thermogenesis, gastric distension, glucose absorption modulation).

What “GLP-1 supplement” means in practice

GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted by intestinal L-cells in response to food. It binds the GLP-1 receptor on pancreatic beta cells (driving glucose-dependent insulin secretion), on the stomach (delaying gastric emptying), and on the hypothalamus and brainstem (driving satiety). Drucker’s 2018 canonical pharmacology review in Cell Metabolism catalogues the receptor biology in detail.^[1]

FDA-approved GLP-1 receptor agonist drugs — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, orforglipron — are synthetic molecules engineered to bind the GLP-1 receptor with higher affinity and longer half-life than native GLP-1. They are prescription pharmaceuticals that went through Phase 1, 2, and 3 clinical trials before FDA approval.

An OTC dietary supplement, in contrast, is a regulatory category created by the Dietary Supplement Health and Education Act of 1994 (DSHEA). Supplements are not approved by the FDA before they are marketed. Manufacturers are required to ensure their own product safety; they may make “structure/function” claims (e.g., “supports healthy metabolism”) but may not make drug-disease claims (e.g., “treats obesity”). All structure/function claims must carry the mandatory DSHEA disclaimer.^[17]

When a product is sold as a “GLP-1 supplement”, it is, by definition, not a GLP-1 receptor agonist drug. The phrase is marketing copy that piggy-backs on the search-volume halo around Ozempic, Wegovy, and Zepbound. What is actually in the bottle is typically one of the following:

Ingredient	Actual mechanism	GLP-1 receptor activity?	Pooled weight effect (RCT meta)
Berberine	AMPK activation; intestinal glucose absorption	None	~ −2 kg over 8–24 weeks
Capsaicin / capsinoids	TRPV1 receptor; brown-adipose-tissue thermogenesis	None	~ −70 kcal/day acute intake; small weight effect
Soluble fiber (psyllium, glucomannan, beta-glucan)	Gastric distension; delayed emptying; SCFA	None	~ −0.4 to −1 kg long-term
Chromium picolinate	Modest insulin sensitivity effect (mechanism debated)	None	~ −1.1 kg (Cochrane: “uncertain clinical relevance”)
Apple cider vinegar	Acetate effects on glycemia; appetite via gastric emptying	None	Insufficient evidence to recommend (Launholt 2020)
Proprietary “GLP-1 support” blend	Unknown; usually one or more of the above + filler	None	No blend-specific RCT

For magnitude reference, the FDA-approved GLP-1 receptor agonists produce −14.9% body weight at 68 weeks (semaglutide 2.4 mg, STEP 1^[14]) and −20.9% at 72 weeks (tirzepatide 15 mg, SURMOUNT-1^[15]). The supplement-vs-drug gap is roughly 10x.

Berberine: the “natural Ozempic” claim — what the evidence actually shows

Berberine is a plant alkaloid extracted from Berberis species. The viral TikTok framing of berberine as “nature’s Ozempic” began around 2023 and has driven the entire OTC “GLP-1 supplement” category. The framing is wrong on mechanism and on magnitude.

Berberine’s actual mechanism: AMPK, not GLP-1

Berberine activates AMP-activated protein kinase (AMPK), a cellular energy sensor that downregulates hepatic gluconeogenesis and increases peripheral glucose uptake. It also modulates intestinal glucose absorption and gut microbiota composition. None of these mechanisms is GLP-1 receptor agonism. Yin et al.’s 2008 RCT in Metabolism demonstrated that berberine 500 mg three times daily for 3 months reduced HbA1c from 9.5% to 7.5% and fasting glucose from 10.6 to 6.9 mmol/L in newly diagnosed T2D — effects comparable to metformin in that small study.^[2]

Berberine’s actual weight effect: ~ −2 kg pooled

Lan et al.’s 2015 meta-analysis in Journal of Ethnopharmacology pooled 27 RCTs (n=2,569) of berberine vs lifestyle or active control. The drug was effective on glycemia and lipids; trial quality was variable.^[3] Amini et al.’s 2020 meta-analysis in Complementary Therapies in Medicine focused specifically on anthropometric outcomes (body weight, BMI, waist circumference) and found a small pooled weight reduction of approximately −2 kg at 8–24 weeks — statistically significant but of borderline clinical relevance and heavily diluted by trial heterogeneity.^[4] The 2026 Elahi Vahed meta-analysis in International Journal of Obesity confirmed these findings in the most recent pooled analysis.^[5]

Magnitude comparison

Pooled mean weight reduction from FDA-approved GLP-1 receptor agonist drugs versus the most common 'GLP-1 supplement' ingredients. Berberine, capsaicin, chromium, and fiber each have small, mechanism-unrelated effects on body weight; none acts on the GLP-1 receptor. The supplement-vs-drug magnitude gap is approximately 10x.^[14]^[15]^[4]^[6]^[10]^[11]

Tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % body weight
Prescription GLP-1/GIP receptor agonist
Semaglutide 2.4 mg (STEP 1, 68 wk)14.9 % body weight
Prescription GLP-1 receptor agonist
Berberine (Amini 2020 meta, 8-24 wk)2.5 % body weight
~ -2 kg pooled effect; AMPK mechanism, not GLP-1
Chromium picolinate (Tian 2013 Cochrane, 12-16 wk)1.4 % body weight
~ -1.1 kg; Cochrane: 'uncertain clinical relevance'
Soluble fiber (Wanders 2011 meta, long-term)1 % body weight
~ -0.4 to -1 kg; gastric distension mechanism
Apple cider vinegar (Launholt 2020)0.5 % body weight
Insufficient evidence to recommend

Two kilograms of weight loss over four months is not nothing — it is a real, small effect. But it is also not Ozempic, and it is not driven by the GLP-1 receptor. For the full berberine-vs-Ozempic deep dive, see berberine vs Ozempic: the “nature’s Ozempic” myth.

Capsaicin, fiber, chromium, ACV — the rest of the “GLP-1 supplement” aisle

Capsaicin / capsinoids

Capsaicin is the pungent compound in chili peppers. It activates the TRPV1 receptor, which has been linked to brown adipose tissue (BAT) thermogenesis and sympathetic outflow. Whiting et al.’s 2014 meta-analysis in Appetite pooled RCTs on ad-libitum energy intake and found a modest reduction of approximately −70 to −74 kcal/day in meals following capsaicin ingestion.^[6] A more recent meta-analysis (Zhang 2023, British Journal of Nutrition) confirmed modest body weight and waist-circumference effects.^[7] The mechanism is TRPV1 → sympathetic outflow → BAT thermogenesis (Yoneshiro and Saito, 2013) — not GLP-1 receptor agonism.^[8]

Soluble fiber (psyllium, glucomannan, beta-glucan)

Soluble, viscous, gel-forming fibers slow gastric emptying, distend the stomach, and generate short-chain fatty acids during colonic fermentation. Each of these acts on satiety. Howarth et al.’s 2001 review in Nutrition Reviews catalogued the mechanisms in detail.^[9] Wanders et al.’s 2011 systematic review in Obesity Reviews pooled long-term RCTs and found small but statistically significant body-weight reductions in the range of −0.4 to −1.0 kg, with viscous and gel-forming fibers outperforming non-viscous fibers.^[10] Again: the satiety mechanism is gastric and microbial, not GLP-1 receptor agonism.

Chromium picolinate

Chromium picolinate is one of the most-studied OTC weight-loss supplements. The 2013 Cochrane systematic review (Tian et al.) pooled 9 RCTs (n=622) and found a mean weight loss of approximately −1.1 kg at 12–16 weeks — statistically significant but described by the Cochrane authors verbatim as “of uncertain clinical relevance” and “questionable.” Overall quality of evidence was rated low.^[11] The mechanism, debated for decades, has nothing to do with GLP-1.

Apple cider vinegar

Apple cider vinegar (ACV) sits at the top of the “natural Ozempic” search results. The Launholt et al. 2020 systematic review in European Journal of Nutrition concluded that the evidence was “inconsistent” and “limited,” and that there was insufficient evidence to recommend ACV for weight management. The review also documented safety signals at high doses (dental erosion, throat irritation, hypokalemia).^[12] The most recent meta-analysis (Castagna et al., 2025, Nutrients) pooled RCTs in T2D and overweight populations and found small body-composition effects with high heterogeneity.^[13] A 2024 ACV weight-loss trial (Abou-Khalil et al.) was retracted in September 2025 over data integrity concerns and should not be cited.

“Proprietary GLP-1 support” blends

Many products on Amazon are not single ingredients but proprietary blends — a few of the ingredients above plus chromium, green tea extract, garcinia cambogia, l-carnitine, gymnema sylvestre, alpha-lipoic acid, or whatever is trending. The combined dose of any single evidence-supported ingredient is often below the dose used in the clinical-trial literature. There are no published RCTs of these specific blends. The product’s effect is, at best, a fraction of the already-small effect of its strongest single ingredient. For the deeper 16-ingredient evidence-grade breakdown, see weight-loss supplements vs GLP-1: evidence grade and our interactive supplement evidence grader.

What separates a supplement from an FDA-approved GLP-1

The regulatory distinction is large and not widely understood. Dietary supplements and FDA-approved drugs are governed by different statutes, different evidence standards, and different marketing rules.

Requirement	FDA-approved GLP-1 drug	“GLP-1” supplement
Pre-market FDA review	Required (NDA, Phase 1-3 trials)	Not required
Manufacturer must prove efficacy	Yes — Phase 3 RCTs	No
Manufacturer must prove safety	Yes — preclinical + clinical	Self-affirmed; no FDA review
May claim to treat obesity	Yes (if approved indication)	No — DSHEA prohibits drug-disease claims
Required disclaimer	Boxed warning, FDA-approved labeling	“These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.”
Prescription required	Yes	No

DSHEA permits manufacturers to make “structure/function” claims such as “supports healthy weight management” or “promotes appetite balance,” but it prohibits claims that a supplement treats, prevents, or cures a disease — including obesity. Marketing copy that describes a supplement as a replacement for or equivalent to Ozempic, Wegovy, or any prescription GLP-1 crosses that line and is grounds for an FDA Warning Letter or FTC enforcement action.^[17]

FTC and FDA enforcement on “natural Ozempic” supplements

Federal enforcement against fraudulent weight-loss supplements is not new. Two agencies act in parallel.

FTC v. Redwood Scientific Technologies (Cardiff)

In 2018 the Federal Trade Commission filed case 172-3117-X190001 against Jason Cardiff and Redwood Scientific Technologies, Inc. The complaint targeted deceptive weight-loss and smoking-cessation supplement and strip products that were marketed as having scientifically validated physiological effects without supporting clinical evidence. The case ended in a 2020 default judgment.^[16] The case is the most direct federal precedent for false-advertising actions against OTC supplement-format weight-loss products and applies equally to the current wave of “natural Ozempic” marketing.

FDA Tainted Weight Loss Products database

The FDA maintains an ongoing public-health alert and database of weight-loss dietary supplements found to contain undisclosed pharmaceutical ingredients. The list has historically included sibutramine (a withdrawn anorectic), phenolphthalein (a withdrawn laxative now classified as a probable carcinogen), and ephedra alkaloids. Products in this database are not legally dietary supplements; they are unapproved new drugs subject to FDA seizure and recall.^[18]

FDA Warning Letters on supplement marketing

The FDA Warning Letters database includes routine actions against supplement companies whose marketing copy crosses from DSHEA-permitted structure/function claims into prohibited drug-disease claims about weight loss. The specific trigger phrases that attract Warning Letters include direct comparisons to Ozempic, Wegovy, Zepbound, or “GLP-1,” claims of treating or curing obesity, and claims of producing percentage body-weight reductions matching the prescription drugs.

Red flags on any “GLP-1 supplement” listing

Direct comparison to semaglutide, Ozempic, Wegovy, tirzepatide, or Zepbound.
Claims of percentage body-weight reduction matching prescription GLP-1 trials (15–20%).
No FDA approval number, no NDA number, no DailyMed entry.
The phrase “natural Ozempic” or “GLP-1 support” on the label.
Sold without prescription on Amazon, TikTok Shop, MLM sites, or unbranded e-commerce.
Mechanism described as “activates GLP-1” without a citation to a peer-reviewed RCT in humans.

If a supplement helps you, the mechanism is not GLP-1

There is a more honest version of the question. Do any OTC supplements help with weight loss at all? The answer is a qualified yes — small, mechanism-specific, mostly disappointing compared to the prescription drugs.

Soluble fiber can produce a small additional weight loss when added to a calorie-controlled diet. The mechanism is gastric distension and microbiome fermentation. It is the best-evidenced OTC option for an appetite effect.
Caffeine and green tea catechins produce a small increase in resting energy expenditure. The effect is real, mechanism is sympathetic / thermogenic, and the magnitude is roughly 50–100 kcal/day — useful as a marginal lever, not a primary intervention.
Berberine improves glycemia in T2D and produces a small weight effect. If glycemic control is the actual goal, this is one of the better-evidenced supplements. The mechanism is AMPK, not GLP-1.
Capsaicin reduces ad-libitum energy intake in the meal following ingestion. Mechanism is TRPV1 / BAT. Magnitude is modest.

For people who cannot access a prescription GLP-1, these supplements are small marginal levers stacked on top of the actual primary interventions: structured calorie deficit, adequate protein (1.2–1.6 g/kg/day), progressive resistance training, and the FDA-approved non-GLP-1 anti-obesity medications (phentermine, phentermine/topiramate Qsymia, naltrexone/bupropion Contrave, orlistat Xenical/Alli).

For the full FDA-approved GLP-1 reference — brand, manufacturer, approved indications, dose ladder, and DailyMed prescribing information for every approved GLP-1 receptor agonist — see our full GLP-1 medication list. For the broader debunker on transdermal GLP-1 patches, see are GLP-1 patches real? evidence review. For the broader peptide landscape (BPC-157, AOD-9604, retatrutide, cagrisema), see peptides for weight loss: evidence review.

Bottom line

No OTC dietary supplement contains a GLP-1 receptor agonist. By definition, a supplement cannot be a GLP-1 drug.
The ingredients sold as “GLP-1 supplements” — berberine, capsaicin, fiber, chromium, apple cider vinegar — act on unrelated pathways (AMPK, TRPV1, gastric distension, insulin sensitivity). None binds the GLP-1 receptor.
Pooled effect sizes for these ingredients run roughly 1–2 kg (about 1–2% body weight) over 8–24 weeks. The FDA-approved GLP-1 drugs produce 14.9% (semaglutide, STEP 1) to 20.9% (tirzepatide, SURMOUNT-1) at 68–72 weeks. The gap is roughly 10x.
DSHEA (21 U.S.C. §§ 321(ff), 343(r), 343-2, 350b) prohibits supplements from making drug-disease claims. Marketing a supplement as a substitute for Ozempic, Wegovy, or Zepbound crosses that line and is grounds for FTC false-advertising action or FDA Warning Letter.
The FTC has the Cardiff/Redwood Scientific precedent, and the FDA maintains the Tainted Weight Loss Products database and the Warning Letters database to cover the rest.
If you cannot access a prescription GLP-1, the highest-evidence OTC marginal levers are soluble fiber, caffeine, and (for glycemic control specifically) berberine — layered on top of a calorie deficit, adequate protein, and resistance training.

Frequently asked questions

Weight-loss supplements vs GLP-1: evidence grade — 16 of the most-searched OTC supplements graded against peer-reviewed RCT evidence and the magnitude of FDA-approved GLP-1 drugs.
Berberine vs Ozempic: the “nature’s Ozempic” myth — the deep-dive berberine review with the full PubMed evidence chain.
Are GLP-1 patches real? Evidence review — sister debunker on the transdermal-patch hype cluster.
Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
Peptides for weight loss: evidence review — the three categories of weight-loss peptides; which have Phase 3 evidence and which do not.
Supplement evidence grader (tool) — interactive evidence grader scoring OTC supplements on mechanism, RCT support, and magnitude vs FDA-approved GLP-1 drugs.

References

1.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Canonical pharmacology review of native GLP-1, synthetic GLP-1 receptor agonists, and the molecular mechanisms by which the GLP-1 receptor drives glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central satiety signaling. None of the OTC supplement ingredients reviewed in this article act on the GLP-1 receptor. Cell Metab. 2018. PMID: 29617641.
2.Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Three-month RCT in 36 patients with newly-diagnosed T2D: berberine 500 mg three times daily reduced HbA1c from 9.5% to 7.5% and fasting plasma glucose from 10.6 to 6.9 mmol/L — comparable to metformin in this small study. Mechanism is AMPK activation and intestinal glucose absorption modulation, NOT GLP-1 receptor agonism. Metabolism. 2008. PMID: 18442638.
3.Lan J, Zhao Y, Dong F, Yan Z, Zheng Y, Zhou J, Liu J. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Pooled 27 RCTs (n=2,569) finding berberine + lifestyle outperformed lifestyle alone on fasting glucose, HbA1c, and lipid panel in T2D — modest effect sizes; quality of underlying trials was variable. J Ethnopharmacol. 2015. PMID: 25498346.
4.Amini MR, Sheikhhossein F, Naghshi S, Djafari F, Askari M, Shahinfar H, Hashemi R, Shab-Bidar S. Effects of berberine and barberry on anthropometric measures: A systematic review and meta-analysis of randomized controlled trials. Pooled RCTs reporting body weight, BMI, and waist circumference outcomes: berberine produced a small but statistically significant weight reduction (~ -2 kg pooled effect) of borderline clinical relevance and heavily diluted by trial heterogeneity. The effect is not via the GLP-1 receptor. Complement Ther Med. 2020. PMID: 32147051.
5.Elahi Vahed I, Shahir-Roudi E. The effect of berberine on obesity indices: a systematic review and meta-analysis. Most recent (2026) meta-analysis of berberine on body-weight, BMI, and waist-circumference outcomes in human RCTs; modest pooled effects consistent with prior reviews. Quality of underlying trials remains a limitation. Int J Obes (Lond). 2026. PMID: 41310257.
6.Whiting S, Derbyshire EJ, Tiwari B. Could capsaicinoids help to support weight management? A systematic review and meta-analysis of energy intake data. Pooled RCTs of capsaicin / capsinoid intake on ad-libitum energy intake: pooled mean reduction of approximately -70 to -74 kcal/day in the meal following capsaicin ingestion. Modest acute effect; long-term body-weight trials are weaker. Mechanism is TRPV1-mediated, not GLP-1 receptor agonism. Appetite. 2014. PMID: 24246368.
7.Zhang W, Zhang Q, Wang L, Zhou Q, Wang H, Zhang Y, Zhang T, Sun M. The effects of capsaicin intake on weight loss among overweight and obese subjects: a systematic review and meta-analysis of randomised controlled trials. More recent capsaicin / weight-loss meta-analysis — modest effects on body weight and waist circumference; mechanism remains TRPV1 / brown-adipose-tissue thermogenesis, not GLP-1. Br J Nutr. 2023. PMID: 36938807.
8.Yoneshiro T, Saito M. Transient receptor potential activated brown fat thermogenesis as a target of food ingredients for obesity management. Mechanistic review of capsaicin / capsinoid action on TRPV1 receptors in brown adipose tissue, increasing sympathetic outflow and BAT thermogenesis. Establishes that the metabolic effect of capsaicin is mediated through TRPV1 → BAT, not through the GLP-1 receptor. Curr Opin Clin Nutr Metab Care. 2013. PMID: 24100669.
9.Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Comprehensive review of fiber-induced satiety mechanisms: gastric distension, delayed gastric emptying, short-chain fatty acid generation by colonic fermentation, and small effects on body weight in long-term cohorts. The satiety mechanism is volumetric and microbiome-mediated, not GLP-1 receptor agonism. Nutr Rev. 2001. PMID: 11396693.
10.Wanders AJ, van den Borne JJ, de Graaf C, Hulshof T, Jonathan MC, Kristensen M, Mars M, Schols HA, Feskens EJ. Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials. Pooled RCTs found viscous and gel-forming fibres produced statistically significant but small body-weight reductions (mean -0.4 to -1.0 kg in long-term trials). Effect size is modest and heterogeneous. Obes Rev. 2011. PMID: 21676152.
11.Tian H, Guo X, Wang X, He L, Lv R, Yang T, Wang H, Hua F, Lin H, Yang Y. Chromium picolinate supplementation for overweight or obese adults. Cochrane systematic review of 9 RCTs (n=622) of chromium picolinate vs placebo. Pooled mean weight loss was approximately -1.1 kg at 12-16 weeks, which the authors characterized as 'of uncertain clinical relevance' and 'questionable.' Quality of evidence rated low. Cochrane Database Syst Rev. 2013. PMID: 24293292.
12.Launholt TL, Kristiansen CB, Hjorth P. Safety and side effects of apple vinegar intake and its effect on metabolic parameters and body weight: a systematic review. Reviewed RCTs of apple cider vinegar on body weight and metabolic parameters; concluded the evidence was 'inconsistent' and 'limited' and that there is insufficient evidence to recommend ACV for weight management. Includes safety signals (dental erosion, throat irritation, hypokalemia at high doses). Eur J Nutr. 2020. PMID: 32170375.
13.Castagna A, Ferro Y, Noto FR, Pujia R, Mazza E, Tirinato L, Pujia A, Montalcini T, Maurotti S. Effect of Apple Cider Vinegar Intake on Body Composition in Humans with Type 2 Diabetes and/or Overweight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Most recent ACV body-composition meta-analysis (2025); pooled effects on body weight, BMI, and waist circumference are small with high heterogeneity. Companion note: a 2024 ACV trial (Abou-Khalil) was retracted in September 2025 for data integrity concerns and should not be cited. Nutrients. 2025. PMID: 41010525.
14.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg weekly produced mean body-weight reduction of -14.9% vs -2.4% placebo at 68 weeks. Used here as magnitude contrast against OTC supplements. N Engl J Med. 2021. PMID: 33567185.
15.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Tirzepatide 15 mg weekly produced mean body-weight reduction of -20.9% vs -3.1% placebo at 72 weeks. Used here as magnitude contrast against OTC supplements. N Engl J Med. 2022. PMID: 35658024.
16.U.S. Federal Trade Commission. Jason Cardiff (Redwood Scientific Technologies, Inc.) — FTC case 172-3117-X190001. 2018 enforcement action against deceptive weight-loss and smoking-cessation supplement strip products that claimed scientifically validated physiological effects without supporting clinical evidence. Default judgment 2020. Cited as the most direct federal precedent for false weight-loss claims on OTC supplement-format products. U.S. Federal Trade Commission. 2020. https://www.ftc.gov/legal-library/browse/cases-proceedings/172-3117-x190001-jason-cardiff-redwood-scientific-technologies-inc
17.U.S. Congress. Dietary Supplement Health and Education Act of 1994 (DSHEA), Pub. L. 103-417, 108 Stat. 4325; codified at 21 U.S.C. §§ 321(ff), 343(r), 343-2, 350b. Statute defining 'dietary supplement,' permitting structure/function claims with mandatory disclaimers, prohibiting drug-disease claims on supplements, and placing the burden of safety substantiation on the manufacturer rather than on FDA pre-market review. Public Law 103-417. 1994. https://www.congress.gov/bill/103rd-congress/senate-bill/784
18.U.S. Food and Drug Administration. Tainted Weight Loss Products — ongoing public health alert and database of weight-loss dietary supplements found to contain undisclosed pharmaceutical ingredients (e.g., sibutramine, phenolphthalein, ephedra alkaloids) and products making fraudulent weight-loss claims. Companion: FDA Warning Letters database. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/medication-health-fraud/tainted-weight-loss-products

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. “GLP-1 supplements” is a YMYL (Your Money or Your Life) topic. Every regulatory and pharmacology claim in this article is anchored to a primary source (PubMed, FDA, FTC, or DSHEA statute) and should be independently verified by your prescriber. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication, dietary supplement, or OTC weight-loss product. Product categories are described generically; no individual seller or brand is named.